Oruka Therapeutics, Inc. (ORKA)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on ORKA

With Tiblio's Option Bot, you can configure your own wheel strategy including ORKA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ORKA
  • Rev/Share 0.0
  • Book/Share 8.7507
  • PB 1.6216
  • Debt/Equity 0.0026
  • CurrentRatio 30.0335
  • ROIC -0.232

 

  • MktCap 531280695.0
  • FreeCF/Share -1.7933
  • PFCF -7.1078
  • PE -7.8436
  • Debt/Assets 0.0025
  • DivYield 1.3641
  • ROE -0.2688

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ORKA BTIG Research -- Buy -- $44 May 22, 2025
Initiation ORKA Wolfe Research -- Outperform -- $20 Feb. 4, 2025
Initiation ORKA Stifel -- Buy -- $49 Oct. 11, 2024
Initiation ORKA H.C. Wainwright -- Buy -- $45 Oct. 7, 2024
Initiation ORKA Leerink Partners -- Outperform -- $44 Sept. 17, 2024
Initiation ORKA TD Cowen -- Buy -- -- Sept. 16, 2024
Initiation ORKA Jefferies -- Buy -- $40 Sept. 13, 2024

News

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
ORKA
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026

Read More
image for news Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
Oruka Therapeutics to Present at Multiple March Investor Conferences
ORKA
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

Read More
image for news Oruka Therapeutics to Present at Multiple March Investor Conferences

About Oruka Therapeutics, Inc. (ORKA)

  • IPO Date
  • Website http://www.orukatx.com
  • Industry Biotechnology
  • CEO Lawrence Otto Klein
  • Employees 28

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.